Hemorrhage and coagulopathy in the critically ill

Emergency Medicine Clinics of North America

Volumn 32, Issue 4, 2014, Pages 797-810

  Paterson, Tara Ann ^a   Stein, Deborah Michelle ^b  

^a R ADAMS COWLEY SHOCK TRAUMA CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulopathy; Hemorrhage; Massive transfusion protocol; Resuscitation; Transfusion

Indexed keywords

ACTIVATED CARBON; APIXABAN; DABIGATRAN; FRESH FROZEN PLASMA; HEMOGLOBIN; HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TRANEXAMIC ACID; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

ACIDOSIS; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD STORAGE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; BRAIN HEMORRHAGE; CONGESTIVE HEART FAILURE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE TRANSMISSION; DRUG COST; ERYTHROCYTE CONCENTRATE; HEMATOCRIT; HEMODIALYSIS; HEMOPERFUSION; HEMOPHILIA; HUMAN; HYPOTHERMIA; HYPOVOLEMIC SHOCK; INJURY SEVERITY; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EDEMA; MORTALITY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN TIME; REVIEW; SEIZURE; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBOSIS; TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD; TRANSFUSION RELATED ACUTE LUNG INJURY; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT; BLOOD CLOTTING; BLOOD COAGULATION DISORDERS; CLINICAL PROTOCOL; HEMORRHAGE; PATHOPHYSIOLOGY; PHYSIOLOGY; STANDARDS;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; CLINICAL PROTOCOLS; CRITICAL ILLNESS; HEMORRHAGE; HUMANS; HYPOTHERMIA; THROMBELASTOGRAPHY; VITAMIN K;

EID: 84913526404     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.emc.2014.07.005     Document Type: Review

References (75)

1. Hess J.R., Schmidt P.J. The first blood banker: Oswald Hope Robertson. Transfusion 2000, 40:110-113.
2. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.
3. Brohi K., Cohen M.J., Davenport R.A. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 2007, 13:680-685.
4. Dzik W.H. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep 2004, 3(5):324-330.
5. Hunt H., Hyde C., Stanworth S., et al. Thromboelastography (TEG) and thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev 2013, (3). CD010438. 10.1002/14651858.CD010438.
6. Schochl H., Voelckl W., Grassetto A., et al. Practical application of point of care coagulation testing to guide treatment decisions in trauma. JTrauma Acute Care Surg 2013, 74(6):1587-1598.
7. Tapia N.M., Chang A., Norman M., et al. TEG-guided resuscitation is superior to standardized MTP resuscitation in massively transfused penetrating trauma patients. JTrauma Acute Care Surg 2013, 74:378-385. [discussion: 385-6].
8. Berger S., Salhanick S.D., Chase M., et al. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med 2013, 61(4):475-479.
9. Brohi K., Singh J., Heron M., et al. Acute traumatic coagulopathy. JTrauma 2003, 54(6):1127-1130.
10. Holcomb J.B., McMullin N.R., Pearse L., et al. Causes of death in U.S. Special Operations forces in the global war on terrorism. Ann Surg 2007, 245(6):968-991.
11. Napolitano L.M., Kurek S., Luchette F.A., et al. Clinical practice guidelines: red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009, 37(12):3124-3157.
12. Elmer J., Wilcox S.R., Raja A.S. Massive transfusion in hemorrhagic shock. JEmerg Med 2012, 44(4):829-838.
13. Brohi K., Cohen M.J., Ganter M.T., et al. Acute traumatic coagulopathy: initiated by hypoperfusion; modulated through protein C pathway?. Ann Surg 2007, 245:812-818.
14. Mitra B., Cameron P.A., Gruen R.L., et al. The definition of massive transfusion in trauma: a critical variable in examining evidence for resuscitation. Eur J Emerg Med 2011, 18(3):137-142.
15. Savage S.A., Zarzaur B.L., Croce M.A., et al. Redefining massive transfusion when every second counts. JTrauma Acute Care Surg 2013, 74(2):396-400. [discussion: 400-2].
16. Levy J.H., Dutton R.P., Hemphill J.C., et al. Multidisciplinary approach to the challenge of hemostasis. Anesth Analg 2010, 110:354-364.
17. Holcomb J.B., Hess J.R. Early massive transfusion for trauma: state of the art: editor's introduction. JTrauma 2006, 60(6 Suppl):S1-S2.
18. Malone D.L., Hess J.R., Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. JTrauma 2006, 60(6 Suppl):S91-S96.
19. Holcomb J.B., Jenkins D., Rhee P., et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. JTrauma 2007, 62(2):307-310.
20. Davenport R., Manson J., De'Ath H., et al. Functional definition and characterization of acute trauma coagulopathy. Crit Care Med 2011, 39:2652-2658.
21. Murthi S.B., Stansbury L.G., Dutton R.P., et al. Transfusion medicine in trauma patients: an update. Expert Rev Hematol 2011, 4(5):527-537.
22. Holcomb J.B., del Junco D.J., Fox E.E., et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study. Comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg 2013, 148(2):127-136.
23. Inaba K., Branco B.C., Rhee P., et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. JAm Coll Surg 2010, 210:957-965.
24. Sambasivan C.N., Kunio N.R., Nair P.V., et al. High ratios of plasma and platelets to packed red blood cells do not affect mortality in nonmassively transfused patients. JTrauma 2011, 71:S329-S336.
25. Goodnough L.T., Levy J.H., Murphy M.F. Blood transfusion 1. Concepts of blood transfusion in adults. Lancet 2013, 381:1845-1854.
26. Lefant C. Transfusion practice should be audited for both undertransfusion and overtransfusion. Transfusion 1992, 32:873-874.
27. Hebert P.C., Wells G., Blajchman M.A., et al. Amulticenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. NEngl J Med 1999, 340:409-417.
28. Wu W.C., Rathore S.S., Wang Y., et al. Blood transfusions in elderly with acute myocardial infarction. NEngl J Med 2001, 345:1230-1236.
29. Carson J.L., Terrin M.L., Noveck H., FOCUS Investigators, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. NEngl J Med 2011, 365(26):2453-2462.
30. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2012 2013, US Food and Drug Administration Center forBiologics Evaluation and Research, Available at:. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm346639.htm.
31. Triulzi D.J. Transfusion-related acute lung injury: current concepts for the clinician. Anesth Analg 2009, 108:770-776.
32. Palfi M., Berg S., Berlin G. Arandomized controlled trial of transfusion-related acute lung injury; is plasma from multiparous blood donors dangerous?. Transfusion 2001, 41:317-322.
33. Dzik W.H., Blajchman M.A., Fergusson D., et al. Clinical review: Canadian National Advisory Committee on blood and blood products-massive transfusion consensus conference 2011: report of the panel. Crit Care 2011, 15:242.
34. Eder A.F., Dy B.A., Perez J.M., et al. The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy. Transfusion 2013, 10.1111/j.1537-2995.2012.03935.x.
35. Vlaar A.P., Binnekade J.M., Prins D., et al. Risk factors and outcome of transfusion related acute lung injury in the critically ill: a nested case-control study. Crit Care Med 2010, 38(3):771-777.
36. Murphy E.L., Kwaan N., Looney M.R., et al. Risk factors and outcomes in transfusion-associated circulatory overload. Am J Med 2013, 126:357.e29-357.e38.
37. Yazer M., Eder A.F., Land K.J. How we manage AB plasma inventory in the blood center and transfusion service. Transfusion 2013, 23(8):1627-1633.
38. Inaba K., Branco B.C., Rhee P., et al. Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients. Arch Surg 2010, 145(9):899-906.
39. Silliman C.C., Moore E.E., Johnson J.L., et al. Transfusion of the injured patient: proceed with caution. Shock 2004, 21:291-299.
40. Vamvakas E.C., Blajchman M.A. Transfusion-related mortality: the ongoing risks of allogenic blood transfusion and the available strategies for their prevention. Blood 2009, 113(15):3406-3417.
41. Alam H.B., Bice L.M., Butt M.U., et al. Testing of blood products in a polytrauma model: results of a Multi-Institutional Randomized Preclinical Trial. JTrauma 2009, 67:856-864.
42. Alam H.B., Velmahos G.C. Trends in resuscitation. Curr Probl Surg 2011, 48(8):531-564.
43. Uniformed Services University of the Health Sciences Combat fluid resuscitation 2001, Sponsored by US Office of Naval Research; US Army Medical Research and Material Command, Department of Surgery, Department of Military and Emergency Medicine, Bethesda (MD).
44. Koch C.G., Li L., Sessler D.I., et al. Duration of red-cell storage and complications after cardiac surgery. NEngl J Med 2008, 358(12):1229-1239.
45. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatraban versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361(12):1139-1151.
46. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban verses warfarin in nonvalvular atrial fibrillation. NEngl J Med 2013, 365(10):883-891.
47. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban verses warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365(11):981-992.
48. Raja A.S., Geyer B. Emergency department management of patients on novel oral anticoagulant agents. Emerg Med Pract 2013, 15(10):1-19.
49. Yang L., Stanworth S., Hopewell S., et al. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion 2012, 52:1673-1686.
50. Etemadrezaie H., Baharvahdat H., Shariati Z., et al. The effect of fresh frozen plasma in severe closed head injury. Clin Neurol Neurosurg 2007, 109:166-171.
51. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris V.A., Brown J.R., et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011, 91:944-982.
52. Zhou W., Schwarting S., Illanes S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with direct thrombin inhibitor dabigatraban. Stroke 2011, 42(12):3594-3599.
53. Meehan R., Tavares M., Sweeney J. Clinical experience with oral versus intravenous vitamin K for warfarin reversal. Transfusion 2013, 53(3):491-498.
54. Guyatt G.H., Akl E.A., Crowther M., American College of Chest Physicians, et al. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:10s.
55. Kenet G., Walden R., Eldad A., et al. Treatment of traumatic bleeding with recombinant factor VIIa. Surgical intervention failed to stop life-threatening bleeding caused by injury complicated by severe coagulopathy. Administration of recombinant factor VIIa immediately corrected the coagulopathy and bleeding stopped. Lancet 1999, 354:1879.
56. Warkentin T.E., Margetts P., Connolly S.J., et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012, 119(9):2172-2174.
57. Boffard K.D., Riou B., Warren B., et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized placebo-controlled, double-blind clinical trials. JTrauma 2006, 59:8-15.
58. Hauser C.J., Boffard K., Dutton R., CONTROL Study Group, et al. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. JTrauma 2010, 69(3):489-500.
59. Dutton R.P., Hess J.R., Scalea T.M. Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. JClin Anesth 2003, 15(3):184-188.
60. Stein D.M., Dutton R.P., Kramer M.E., et al. Recombinant factor VIIa: Decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. JTrauma 2008, 64(3):620-628.
61. Stein D.M., Dutton R.P., Kramer M.E., et al. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. JTrauma 2009, 66(1):63-72.
62. Stein D.M., Dutton R.P., Hess J.R., et al. Low dose recombinant factor VIIa for trauma patients with coagulopathy. Injury 2008, 39:1054-1061.
63. Thomas G.O., Dutton R.P., Hemlock B., et al. Thromboembolic complications associated with factor VIIa administration. JTrauma 2007, 62(3):564-569.
64. Quick J.A., Bartels A.N., Coughenour J.P., et al. Experience with prothrombin complex for the emergent reversal of anticoagulation in rural geriatric trauma patients. Surgery 2012, 152:722-728.
65. Sarode R., Milling T.J., Refaai M.A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding. A randomized, plasma-controlled, phase IIIb study. Circulation 2013, 128:1234-1243.
66. Sorenson B., Spahn D.R., Innerhofer P., et al. Clinical review: prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care 2011, 15:201.
67. Dager W.E., Gosselin R.C., Roberts A.J. Reversing dabigatraban in life-threatening bleeding during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013, 41(5):e42-e46.
68. Pernod G., Albaladejo P., Godier A., et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative hameostasis (GIHP). Arch Cardiovasc Dis 2013, 106(6-7):382-393.
69. Kaatz S., Kouides P.A., Garcia D.A., et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012, 87:S141-S145.
70. Shakur H., Roberts I., Bautista R., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant hemorrhage (CRASH-2): a randomized, placebo-controlled trial. Lancet 2010, 376(9734):23-32.
71. Roberts I., Shakur H., Afolabi A., et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomized controlled trial. Lancet 2011, 377(9771):1096-1101.
72. Kashuk J.L., Moore E.E., Johnson J.L., et al. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer?. JTrauma 2008, 65:261-270.
73. Morrison J.J., Dubose J.J., Rasmussen T.E., et al. Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg 2012, 147:113.
74. Schwinn D.A., Mackensen G.B., Brown E.N. Understanding the TXA seizure connection. JClin Invest 2012, 122(12):4339-4341. 10.1172/JCI66724.
75. Heckbert S.R., Vedder N.B., Hoffman W., et al. Outcome after hemorrhagic shock in trauma patients. JTrauma 1998, 45(3):545-549.